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Tie-1 is an endothelial speciﬁc receptor tyrosine kinase that is upregulated in diseases such as ath-
erosclerosis and rheumatoid arthritis. We recently demonstrated that Tie-1 induced a proinﬂamma-
tory response when overexpressed in endothelial cells. Here, we used a complementary approach
and suppressed endogenous Tie-1 expression in endothelial cells to examine its function by micro-
array analysis. Tie-1 appeared to govern expression of many genes involved in inﬂammation.
Expression knockdown of Tie-1 signiﬁcantly reduced endothelial conditioned medium ability to
stimulate MCP-1 production in U937 cells. Collectively, our results support the notion that Tie-1
has an inﬂammatory function in endothelial cells.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tie-1 is a receptor tyrosine kinase speciﬁcally expressed in
endothelial cells. Genetic deletion of Tie-1 induced embryonic
lethality with extensive hemorrhage and edema. However, it is be-
lieved that Tie-1 is not required for vasculogenesis but essential in
maintenance of microvasculature in murine embryonic develop-
ment [1,2].
Tie-1 may play a role in inﬂammatory diseases. Endogenous
Tie-1 mRNA is upregulated in atherosclerotic lesions from ApoE-
null mice [3]. Immunostaining reveals that Tie-1 protein is ex-
pressed in endothelial cells in samples of rheumatoid arthritis
[4,5]. Jin et al. showed that adenoviral overexpression of a soluble
extracellular form of Tie-1 could reduce inﬂammation and destruc-
tion of joints in a collagen-induced arthritis model in mice [6], sug-
gesting that Tie-1 may play a functional role in this disease.
Functional analysis of Tie-1 has been hampered by the fact
that a high afﬁnity binding, signaling ligand has not been conclu-
sively identiﬁed. We recently showed that overexpressing mouse
Tie-1 in human endothelial cells in vitro induced Tie-1 phosphor-
ylation and an inﬂammatory response [7]. In this report, we used
a complementary approach and examined the function of endo-chemical Societies. Published by E
thelial cell
n).genous Tie-1 in endothelial cells by siRNA knockdown and
microarray analysis. Our results indicate that suppression of
endogenous Tie-1 expression in endothelial cells downregulates
multiple proinﬂammatory genes, supporting the notion that
Tie-1 activity induces inﬂammation in endothelial cells.2. Materials and methods
2.1. Cell culture
HUVECs (human umbilical vein endothelial cells) and U937
cells were maintained as described [8].
2.2. siRNA knockdown
Three siRNA duplexes against human Tie-1 were purchased
from Invitrogen: #1—GGCCUCAGAACUGGAGUUCAACUUA; #2—
GGGCCUGUAAGAACCGAGGUUACUU; #3—GCAGCCUCGAAACUGU-
GACGAUGAA. A non-targeting control stealth siRNA (cat. #12935-
300) was also purchased (Invitrogen). HUVECs (300000 cells/2 ml)
were seeded on Matrigel coated (1:500 dilution) 6 well plates in
EBM-2 supplemented with additional VEGF (10 ng/ml, R and D)
and EGF (50 ng/ml, Invitrogen). Next day, cells were transfected
with 70 nM siRNA in the presence of 0.09% (v/v) Silentfect
(Bio-Rad). After overnight incubation, cells were grown in freshlsevier B.V. All rights reserved.
Fig. 1. Western blots showing effective knockdown of Tie-1 protein by siRNA. (1)
Control siRNA; (2) Tie-1 siRNA #1.
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(Qiagen). Western blots of Tie-1 were performed as described [7].
2.3. Microarray
HUVECs were transfected with either a control siRNA or
human-Tie-1 speciﬁc siRNA #1 in triplicate. RNA samples were
submitted to Cogenic (Morrisville, NC), a service contract company,
for microarray analysis. Brieﬂy, total RNA (500 ng) was converted
into labeled cRNA with nucleotides coupled to ﬂuorescent dye
Cy3 using the Low RNA Input Linear Ampliﬁcation Kit (Agilent
Technologies, Palo Alto, CA) following the manufacturer’s protocol.
Quality of the samples was veriﬁed by using an Agilent Bioana-
lyzer. Cy3-labeled cRNA (1.65 lg) from each sample was hybrid-
ized to an Agilent Human microarray in 4  44 K format (whole
genome). The hybridized arrays were then washed and scanned,
and data were extracted from the scanned images using Feature
Extraction version 9.5 (Agilent Technologies). Data were combined
into two groups: Tie-1-siRNA-treated samples and control-siRNA-
treated samples. A ratio experiment deﬁnition (ED) was built using
these two groups in Rosetta Resolver. In this ED, the control group
was considered the denominator. Using this ratio ED, genes were
considered differentially expressed if the log (Ratio) P-value was
<0.001 and the absolute fold change was >2.5-fold. This list of
genes was adjusted for multiple testing hypothesis using the
one-way ANOVA analysis and the Benjamin-Hochberg false discov-
ery rate calculation (P-value < 0.01).
2.4. Real-time PCR and western blots
Real-time (Taq-man) PCR protocols and primer sequences for
VCAM-1, ICAM-1, and E-selectin were reported previously [7].
The following real-time PCR probes were purchased from Applied
Biosystems:
Tie-1 50-CTCATGTGGGCGCGGCGGTGGACCT -30;
CXCL5 50-AGAAAATTTTGGACGGTGGAAACAA -30;
Complement 3 50-GGACAAGAAAGGGATCTGTGTGGCA -30;
DARC 50-TCTGGACCTGCTGCTGAACCTGGCA -30;
C15orf48 50-GGAAAACCGATGTGATCCTTGATCG -30;
TNFRSF9 50-GTCGACCCTGGACAAACTGTTCTTT -30;
TLR2 50-GGAGTTCTCCCAGTGTTTGGTGTTG -30;
GM-CSF 50-GAAATGTTTGACCTCCAGGAGCCGA -30;
IL-1b 50-ACAGCTGGAGAGTGTAGATCCCAAA -30;
Tie-2 50-AGCTTCTATCGGACTCCCTCCTCCA -30;
eNOS 50-GGAGAATGGAGAGAGCTTTGCAGCT -30;
TGF-b 50-GACATCAACGGGTTCACTACCGGCC -30.
The primer for a gene of interest was multiplexed with a GAPDH
primer for normalization (Applied Biosystems, cat. #4310884E).
Antibodies against Tie-1 and a-actinin were purchased from Santa
Cruz Biotechnology (cat. # SC-342 and SC-7454).
2.5. U937 stimulation
U937 (200000 cells/0.5 ml) in 0.5%FBS RPMI (ATCC) was seeded
in a 24well plate and serum starved overnight. Next morning,
cells were stimulated with HUVEC conditioned medium (300 ll
used per well) for 4 h prior to harvesting RNAs.
3. Results and discussion
3.1. Identiﬁcation of genes regulated by Tie-1 expression in HUVECs
using siRNA and microarray analysis
Previously, we demonstrated that adenoviral-induced overex-
pression of Tie-1 in human umbilical vein endothelial cells (HU-VECs) and human aortic endothelial cells induced signiﬁcant
upregulation of ICAM-1, VCAM-1, and E-selectin in vitro [7]. There-
fore, Tie-1 may be proinﬂammatory in endothelial cells. However,
due to high efﬁciency of transgene expression mediated by adeno-
viral transduction, the consequent Tie-1 expression level was ex-
tremely high in the system and may not accurately reﬂect in vivo
expression level. In this study, we sought to address this issue by
determining the function of endogenous Tie-1 using siRNA and
microarray analysis. Conﬂuent HUVECs were transfected with
either a control siRNA duplex or a human-Tie-1-speciﬁc siRNA
(#1). Treatment with Tie-1 siRNA effective suppressed Tie-1 pro-
tein levels (Fig. 1). Total RNAs were collected 48 h post transfection
and submitted for microarray analysis. Genes were considered to
be Tie-1 targets if the average absolute fold change was equal to
or larger than 2.5. As expected, Tie-1 expression was suppressed
signiﬁcantly (>7-fold) by the siRNA treatment (Table 1). In addi-
tion, we identiﬁed 56 genes that were downregulated and 34 genes
that were upregulated upon Tie-1 knockdown.
Next, we performed real-time PCR analysis to validate some of
the results from the microarray experiment. To demonstrate spec-
iﬁcity of siRNA knockdown, we tested two additional non-overlap-
ping Tie-1 siRNA duplexes (#2 and #3). All three siRNAs efﬁciently
suppressed Tie-1 expression at the protein and RNA levels (Fig. 2
and data not shown). Real-time PCRs showed that VCAM-1,
ICAM-1, and E-selectin were signiﬁcantly upregulated when Tie-
1 was overexpressed, although only E-selectin was identiﬁed as a
Tie-1 target gene in our microarray. We reasoned that the average
downregulation of VCAM-1 and ICAM-1 resulted from Tie-1 knock-
down might not have been large enough and thus ﬁltered out in
the array analysis. These results, together with the Tie-1 overex-
pression results we reported previously, strongly suggest that
Tie-1 modulates VCAM-1, ICAM-1, and E-selectin expression in
endothelial cells.
Eight additional genes from Table 1 were chosen to be validated
next (Fig. 2). They were complement component 3 (C3), Duffy
blood group chemokine receptor (DARC), chromosome 15 open
reading frame 48 (c15orf48), tumor necrosis factor receptor
superfamily member 9 (TNFRSF9), toll-like receptor 2 (TLR2), gran-
ulocyte-macrophage colony stimulating factor (GM-CSF), interleu-
kin-1b (IL-1b), and chemokine CXCL5. All these genes were
concomitantly downregulated as Tie-1 was knocked down by all
three siRNAs tested. As controls, we showed that expression of
Tie-2, eNOS, and TGF-b were not signiﬁcantly suppressed by the
three siRNAs used, with one exception. Tie-1 siRNA #3, but not
#1 or #2, appeared to reduce Tie-2 expression by approximately
40%. This knockdown might be due to the fact that the region of
Table 1
Genes differentially regulated upon Tie-1 knockdown. Bold: endogenous Tie-1. () and (+) indicate down- and up-regulation, respectively.
Gene name Gene symbol Accesion number Fold change
Complement component 3 C3 NM_000064 7.5
Tyrosine kinase with immunoglobulin-like and EGF-like domains TIE1 NM_005424 7.2
Chromosome 15 open reading frame 48 C15or48 NM_032413 5.6
Duffy blood group, chemokine receptor DARC NM_002036 5.5
Toll-like receptor 2 TLR2 NM_003264 4.7
Colony stimulating factor 3 (granulocyte) CSF3 NM_000759 4.7
Tumor necrosis factor receptor superfamily, member 9 TNFRSF9 NM_001561 4.6
Chemokine (C–C motif) ligand 23 CCL23 NM_005064 4.6
Tumor necrosis factor, alpha-induced protein 6 TNFAIP6 NM_007115 4.5
Zinc ﬁnger protein 143 ZNF143 U09850 4.4
C-type lectin domain family 4, member E CLEC4E NM_014358 4.0
Colony stimulating factor 2 (granulocyte–macrophage) CSF2 NM_000758 4.0
Ubiquitin D UBD NM_006398 3.9
Chemokine (C–X–C motif) ligand 5 CXCL5 NM_002994 3.9
Complement component 1, s subcomponent C1S NM_001734 3.7
P70872 (P70872) FliY protein (fragment), partial (5%) THC2440027 XM_373971 3.7
Epstein-Barr virus induced gene 3 EBI3 NM_005755 3.6
Lipocalin 2 LCN2 NM_005564 3.4
Arachidonate 5-lipoxygenase ALOX5 NM_000698 3.4
Oxytocin receptor OXTR NM_000916 3.4
Serpin peptidase inhibitor, clade A member 3 SERPINA3 NM_001085 3.4
Complement component 1, r subcomponent C1R NM_001733 3.3
Papilin, proteoglycan-like sulfated glycoprotein PAPLN NM_173462 3.3
Kynureninase (L-kynurenine hydrolase) KYNU NM_003937 3.3
Hypothetical gene supported by BC008048 LOC440934 CR593560 3.2
Chemokine (C–C motif) ligand 3-like 3 CCL3L3 NM_001001437 3.2
Phospholipase A2, group IVC (cytosolic, calcium-independent) PLA2G4C NM_003706 3.2
High density lipoprotein-binding protein LOC338328 NM_178172 3.2
TNFAIP3 interacting protein 3 TNIP3 NM_024873 3.2
Selectin E (endothelial adhesion molecule 1) SELE NM_000450 3.1
Interleukin 1, beta IL1B NM_000576 3.1
Unknown THC2280799 – 3.1
MHC class I mRNA fragment 3.8-1 (3.8-1) on chromosome 6. 3.8-1 NR_002812 3.1
Family with sequence similarity 135, member A FAM135A NM_020819 3.1
Likely ortholog of mouse lung-inducible Neutralized-related C3HC4 RING domain protein LINCR BC012317 3.0
Guanine nucleotide binding protein (G protein) GNG2 NM_053064 3.0
Superoxide dismutase 2, mitochondrial (SOD2), nuclear gene encoding mitochondrial protein SOD2 NM_000636 3.0
RCSD domain containing 1 RCSD1 NM_052862 3.0
Solute carrier family 26 (sulfate transporter), member 2 SLC26A2 NM_000112 2.9
Complement factor B CFB NM_001710 2.9
Unknown A_24_P767901 – 2.9
Sex comb on midleg-like 1 (Drosophila) SCML1 NM_006746 2.9
Similar to RIKEN cDNA 8030451K01 RP11-50D16.3 AL536879 2.9
PDZK1 interacting protein 1 PDZK1IP1 NM_005764 2.9
Chemokine (C–X–C motif) ligand 6 CXCL6 NM_002993 2.8
Chemokine (C–C motif) ligand 8 CCL8 NM_005623 2.8
full-length cDNA clone CS0DL003YC11 of B cells (Ramos cell line) Cot 25-normalized of Homo sapiens ENST00000361204 CR614040 2.8
Similar to RIKEN cDNA 8030451K01 RP11-50D16.3 NM_001012754 2.7
Phosphatidic acid phosphatase type 2B PPAP2B NM_003713 2.7
UBX domain containing 2 UBXD2 NM_014607 2.7
Chemokine (C–X–C motif) ligand 2 CXCL2 NM_002089 2.7
Interleukin 7 receptor IL7R NM_002185 2.7
Cathepsin S CTSS NM_004079 2.6
Phospholipase A1 member A PLA1A NM_015900 2.6
Chemokine (C–X–C motif) ligand 3 CXCL3 NM_002090 2.6
Superoxide dismutase 2, mitochondrial SOD2 BC016934 2.6
Hypothetical LOC646999 LOC646999 AK096857 2.6
Carnitine O-octanoyltransferase CROT NM_021151 2.5
Keratin 7 KRT7 NM_005556 2.7
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), transcript variant 1 KIT NM_000222 2.7
Secretory protein LOC348174 LOC348174 AK096051 2.7
Stanniocalcin 1 STC1 NM_003155 2.7
Mesoderm speciﬁc transcript homolog MEST NM_002402 2.7
Collagen, type XXI, alpha COL21A1 NM_030820 2.8
Homo sapiens H19, imprinted maternally expressed untranslated mRNA (H19) on chromosome 11 H19 NR_002196 2.8
chromosome 18 open reading frame 20 C18orf20 NM_152728 2.9
Hypothetical LOC147710 LOC147710 XM_097278 2.9
Cytokine-like 1 CYTL1 NM_018659 2.9
Leucine rich repeat containing 17 LRRC17 NM_005824 2.9
Mal, T-cell differentiation protein 2 MAL2 NM_052886 2.9
Adenomatosis polyposis coli down-regulated 1 APCDD1 NM_153000 2.9
Corticotropin releasing hormone binding protein CRHBP NM_001882 3.0
G0/G1switch 2 G0S2 NM_015714 3.1
Inhibin, beta B INHBB NM_002193 3.1
Brain-derived neurotrophic factor (BDNF), transcript variant 1 BDNF NM_170735 3.2
Unknown THC2279735 – 3.4
(continued on next page)
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Table 1 (continued)
Gene name Gene symbol Accesion number Fold change
KIAA1377 KIAA1377 NM_020802 3.4
Unknown A_24_P489649 XM_067448 3.7
Adenomatosis polyposis coli down-regulated 1-like APCDD1L NM_153360 3.7
Hyaluronan and proteoglycan link protein 1 HAPLN1 NM_001884 3.8
chromosome 1 open reading frame 187 C1orf187 AK075558 3.9
Angiopoietin-like 5 ANGPTL5 NM_178127 4.1
if20d02.x1 Melton Normalized Human Islet 4 N4-HIS 1 Homo sapiens cDNA clone IMAGE:5677082 30 BM129308 BM129308 4.2
Periostin, osteoblast speciﬁc factor POSTN NM_006475 4.4
Nance-Horan syndrome (congenital cataracts and dental anomalies) NHS NM_198270 4.5
Intelectin 1 (galactofuranose binding) ITLN1 NM_017625 4.6
Prion protein 2 (dublet) PRND NM_012409 4.7
Cytochrome P450, family 1, subfamily B CYP1B1 NM_000104 4.7
Collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant) COL3A1 NM_000090 4.8
Homo sapiens cDNA FLJ30847 ﬁs, clone FEBRA2002792. [AK055409] ENST00000381158 AK055409 4.9
Transmembrane protein 46 TMEM46 NM_001007538 5.2
ig. 2. Real-time PCR validation of genes regulated by Tie-1 expression. Gene
xpression, normalized to GAPDH level, was determined by real-time PCRs and
resented as mean ± SD. Expression level of the gene of interest when HUVECs were
eated with the control siRNA was arbitrarily set to one and used for normalization.
ie-1 siRNA #3 appeared to partially knock down Tie-2 expression (see text for
xplanations). RNAs from three siRNA transfections were tested (n = 3). P-values
ere determined by t-tests.
1026 B. Chan, V.P. Sukhatme / FEBS Letters 583 (2009) 1023–1028Tie-1 targeted by siRNA #3 had a high sequence homology to Tie-2.
It was possible that Tie-1 siRNA #3 could partly anneal to Tie-2
mRNA, resulting in reduced Tie-2 expression.
3.2. Suppression of Tie-1 expression reduced endothelial cells ability to
stimulate monocytes
Next, we examined whether expression of Tie-1 would affect
the ability of endothelial cells to stimulate monocytes. HUVEC con-
ditioned medium at basal level stimulated expression of cytokine
MCP-1 in U937 cells, a monocytic cell line, in a time dependent
manner (not shown). Four hours of stimulation with basal HUVEC
conditional medium resulted in a modest but statistically signiﬁ-
cant upregulation of MCP-1 in U937 (Fig. 3). This stimulatory effect
was completely abrogated when conditioned medium of Tie-1-siR-
NA #1-treated HUVECs was used, indicating that Tie-1 was critical
for this inﬂammatory property. Treatment of HUVECs with Tie-1
siRNA #2 or #3 also signiﬁcantly reduced the endothelial condi-
tioned medium ability to stimulate MCP-1 production in U937. In
contrast, endothelial conditioned medium was unable to stimulate
IL-1b synthesis in U937, regardless of whether Tie-1 had been
knockdown by siRNAs. We have not identiﬁed the stimulant
responsible for this phenotype. A neutralizing anti-GM-CSF anti-
body inhibited MCP-1 production in U937 stimulated with HUVEC
conditioned medium only by 25% (data not shown). Probably mul-
tiple agents were responsible for the stimulation, since many pro-
inﬂammatory cytokines were present in HUVEC conditioned
medium. Nonetheless, results of this loss-of-function study collec-
tively support the notion that Tie-1 is proinﬂammatory.
3.3. Microarray proﬁling reveals relevance of Tie-1 in inﬂammatory
diseases
To gain insights into the role of Tie-1 may play in human dis-
eases, we queried the gene proﬁle depicted in Table 1 using the
Ingenuity Pathway Analysis program. Of the 91 input genes (from
Table 1), 70 were eligible for functional analysis and 59 were iden-
tiﬁed to have relevance to known diseases. These 59 genes were
further divided according to speciﬁc function annotations and are
shown in Table 2. The top ten scoring functions suggest that Tie-
1 may play a role in autoimmune diseases and inﬂammatory disor-
ders, consistent with our hypothesis that Tie-1 is proinﬂammatory
in endothelial cells. We are particularly interested in atherosclero-
sis and rheumatoid arthritis, because Tie-1 is upregulated in these
diseases [3–5].
Atherosclerosis is a chronic inﬂammatory disease [9,10]. Inter-
estingly, Tie-1 is speciﬁcally expressed in atherosclerosis-prone
sites in the vasculature [3]. Since Tie-1 is proinﬂammatory in endo-
thelial cells in vitro, we postulate that Tie-1 may play a role in ath-
erogenesis by promoting endothelial inﬂammation. The geneF
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p
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Table 2
Disease relevance of genes regulated by Tie-1 expression in HUVECs. Genes identiﬁed in Table 1 were analyzed by the Ingenuity Pathway Analysis Program using the Ingenuity
Knowledge Base as the reference set. Of the 91 input genes (including Tie-1), 70 were eligible for functional analysis, and 59 were identiﬁed to have functions/diseases relevance.
The top 10 functions are presented here. Detailed explanation of the method used to calculate P-values can be obtained from Ingenuity’s Website (https://analysis.ingenuity.com/
pa/info/help/help.htm).
Function annotation P-value Molecules # Molecules
(of 59)
Connective tissue
disorder
6.80E14 ALOX5, BDNF, C1R, CCL8, CCL23, CFB, CLEC4E, COL3A1, CSF2, CSF3, CTSS, CXCL2, CXCL3, CXCL5, CXCL6, G0S2, IL1B, IL7R,
RCSD1, SLC26A2, SOD2, TLR2, TNFAIP6, TNFRSF9
24
Rheumatic disease 5.45E13 ALOX5, BDNF, C1R, CCL8, CCL23, CFB, CLEC4E, CSF2, CSF3, CTSS, CXCL2, CXCL3, CXCL5, CXCL6, G0S2, IL1B, IL7R, RCSD1,
SOD2, TLR2, TNFAIP6, TNFRSF9
22
Arthritis 7.19E13 ALOX5, BDNF, C1R, CCL8, CCL23, CFB, CLEC4E, CSF2, CSF3, CTSS, CXCL2, CXCL3, CXCL5, CXCL6, G0S2, IL1B, IL7R, RCSD1,
SOD2, TLR2, TNFAIP6
21
Autoimmune disease 3.16E12 ALOX5, C1R, C1S, CCL8, CCL23, CFB, CLEC4E, CSF2, CSF3, CXCL2, CXCL3, CXCL5, CXCL6, G0S2, IL1B, IL7R, KIT, RCSD1,
TLR2, TNFAIP6, TNFRSF9
21
Rheumatoid arthritis 7.35E12 ALOX5, C1R, CCL8, CCL23, CFB, CLEC4E, CSF2, CXCL2, CXCL3, CXCL5, CXCL6, G0S2, IL1B, IL7R, RCSD1, TLR2, TNFAIP6 17
Skeletal and
muscular disorder
1.31E11 ALOX5, BDNF, C1R, CCL8, CCL23, CFB, CLEC4E, COL3A1, CSF2, CSF3, CTSS, CXCL2, CXCL3, CXCL5, CXCL6, G0S2, IL1B, IL7R,
RCSD1, SLC26A2, SOD2, TLR2, TNFAIP6, TNFRSF9
24
Immunological
disorder
6.58E11 ALOX5, BDNF, C1R, C1S, CCL8, CCL23, CFB, CLEC4E, CSF2, CSF3, CTSS, CXCL2, CXCL3, CXCL5, CXCL6, G0S2, IL1B, IL7R, KIT,
RCSD1, TLR2, TNFAIP6, TNFRSF9
23
Inﬂammatory
disorder
1.78E10 ALOX5, BDNF, C1R, CCL8, CCL23, CFB, CLEC4E, CSF2, CSF3, CTSS, CXCL2, CXCL3, CXCL5, CXCL6, EBI3, G0S2, IL1B, IL7R, KIT,
POSTN, RCSD1, SELE, SOD2, TLR2, TNFAIP6, TNFRSF9
26
Inﬂammatory
response
2.44E10 ALOX5, CCL8, CCL23, CCL3L3, CSF2, CSF3, CXCL2, CXCL3, CXCL5, CXCL6, DARC, IL1B, LCN2, SELE, SERPINA3, TLR2,
TNFAIP6
17
Cell movement of
phagocytes
1.40E09 CCL8, CCL23, CFB, CSF2, CSF3, CTSS, CXCL3, CXCL5, CXCL6, IL1B, SELE, SERPINA3, TLR2 13
Fig. 3. Tie-1 in HUVECs was essential in stimulation of MCP-1 expression in U937 cells. Conditioned medium of HUVECs treated with control or Tie-1 siRNA was used to
stimulate U937 cells for 4 h. Expression level in unstimulated cells was arbitrarily set to one and used for normalization. MCP-1 (A) or IL-1b (B) expression in U937 was
determined by real-time PCRs. Conditioned media from three siRNA transfections were tested (n = 3). P-values were determined by t-tests.
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evidence for this hypothesis. In additional to the adhesion mole-
cules, expressions of many genes important in atherosclerosis
development were also altered when Tie-1 was knocked down (Ta-
ble 1). For example, IL-1b is a well-known inﬂammation inducer
and plays an instrumental role in the development of atherosclero-
sis [11–14]. Genetic knockout of TLR2 has been shown to be ath-
eroprotective in several mouse models [15–17]. Interestingly,
TLR2 is expressed in endothelial cells at lesion-prone sites [17].Other genes that have also been implicated in atherosclerosis
and were identiﬁed as Tie-1 targets in this study include TNFRSF9
(CD137), GM-CSF (CSF2), and G-CSF (CSF3). TNFRSF9 was detected
at the vessel walls of sites of inﬂammation in vivo in mice [18] and
was upregulated in atherosclerotic arteries in patient samples [19].
Furthermore, injection of TNFRSF9 agonistic antibody in ApoE-null
mice enhanced lesion formation [19]. Administration of exogenous
GM-CSF or C-CSF also signiﬁcantly upregulated atherosclerosis
development in ApoE-null mice maintained in high fat diet [20].
1028 B. Chan, V.P. Sukhatme / FEBS Letters 583 (2009) 1023–1028Therefore, endogenous Tie-1 in endothelial cells appears to regu-
late multiple genes that are critical in atherosclerosis development.
Rheumatoid arthritis (RA) is a chronic systemic inﬂammatory
disease that primarily affects the joints. It is characterized by
hypertrophy of intima of the synovium, leukocyte inﬁltration into
the synovial tissue, and intensive angiogenesis, resulting in the for-
mation of synovial pannus and ultimately cartilage destruction. As
in atherosclerosis, inﬂammation of endothelial cells is believed to
be crucial in the development of the disease [21].
Tie-1 is known to be upregulated in the endothelial cells in le-
sions of rheumatoid arthritis [4,5]. A recently identiﬁed alterna-
tively spliced soluble Tie-1 ectodomain variant was shown to
reduce clinical signs of arthritis in a collagen-induced arthritis
mouse model [6]. However, the exact mechanism underlying this
inhibitory effect was not addressed. Perhaps the soluble Tie-1 pre-
vented endogenous Tie-1 activation and blocked endothelial
inﬂammation by binding to a Tie-1 ligand yet to be identiﬁed. If
our in vitro results could be extended to in vivo systems, suppress-
ing Tie-1 activity would lead to downregulation of IL-1b, VCAM-1,
ICAM-1, E-selectin, CXCL5, and DARC. IL-1b is central in RA devel-
opment [22]. The adhesion molecules are known to play a crucial
role in mediating leukocyte inﬁltration [23], whereas CXCL5 and
DARC are upregulated in the endothelial cells in RA lesions
[24,25]. Therefore, blockade of Tie-1 function may reduce RA by
suppression of the production of these proteins and factors inﬂuen-
tial in the development of the disease.
In conclusion, results presented in this report support the
hypothesis that Tie-1 induces inﬂammation in endothelial cells
in vitro. Experiments using transgenic mice with endogenous
Tie-1 expression level altered will be needed to investigate the
in vivo functions of Tie-1 in different disease models. Such exper-
iments are currently underway.
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